# P08-09 release-trigger admission: generic invention REJECTED

2026-10-08. Bounded prior-art/source screen, no implementation/training/scoring.
Candidate: irreversible release based on ambiguous local signals and uncertain
sensing-to-release latency, with premature-release/target-delivery tradeoff. No
specific new algorithm/property survives the current proposal. Sequential testing,
robust stopping and delayed execution are established. This does NOT assert one
paper solves the exact combined physiological problem or exhaustive novelty clearance.
No precise combined uncertainty/observation/latency model was supplied; absence of
such a model is an admission gap, not a novel constraint.

## Exact objective/observation/latency distinction needed

Stop/command release at time tau; physical release occurs at tau+L, so relevant site
is at execution, not decision. Hidden target/feeder state can change along route;
observations are noisy local signals, not necessarily IID evidence for two fixed
hypotheses. Premature release event/cargo amount, missed target and delay cost must
be defined on physical release, with finite-horizon expiry and irreversibility. Need
specified joint transition/observation/latency model and uncertainty set. Robust
supremum over a distribution family is not just a nominal confidence threshold.
Data/calibration, online observability of L and action/state dependence matter.

These are formulation requirements, not new algorithm claims. Could be modeled as
belief-state constrained stopping/POMDP with delayed action/absorbing release state;
that is a standard modeling route, NOT an admitted invention or proven efficient
solution. No claim that combining all features is covered by a single verified theorem.
No claim that standard e-process/threshold composition beats an optimal comparator.
Need a precise property/bound/complexity or policy-class advantage under identical
uncertainty/objective before an invention experiment can be authorized.

## Prior-art screen (all fetched)

S1 Sequential Hypothesis Testing under Stochastic Deadlines (2007), full paper:
https://proceedings.neurips.cc/paper_files/paper/2007/file/9c82c7143c102b71c593d98d96093fde-Paper.pdf
Stopping/decision policies with time cost and stochastic deadline. Deadline drawn
independent of observations; deadline is NOT sensing/release execution delay and
fixed latent hypotheses are not route-changing target state.

S2 Optimal Learning under Robustness and Time-Consistency (2019 manuscript), full:
https://people.bu.edu/lepstein/files-research/OptimalLearning-Mar3Posted--UpdatedJune-2019.pdf
Prior ambiguity, maxmin stopping/action under partial Brownian information and
per-unit observation cost; robust classical simple-hypothesis testing example.
Not spatial release/uncertain actuator delay, not universal rectangular uncertainty.

S3 Optimal Stopping Rules for Sequential Hypothesis Testing (2017), publisher abstract:
https://drops.dagstuhl.de/entities/document/10.4230/LIPIcs.ESA.2017.32
Established sequential stopping literature; abstract only, no unseen algorithm/bound
claimed as an exact comparator.

S4 Bayesian Sequential Experimentation with Delayed Response (2017), full paper:
https://eprints.whiterose.ac.uk/id/eprint/110768/1/delaypaperDriver.pdf
Delayed observed endpoint and benefits-minus-sampling cost optimal boundaries.
Delayed observations, not delayed execution, explicitly distinguished.

S5 Some results on optimal stopping under phase-type distributed implementation delay
(2020), publisher full HTML and institutional abstract:
https://link.springer.com/article/10.1007/s00186-019-00694-6
https://www.utupub.fi/items/cfc8f1a6-b630-4137-a79a-1f8d9f57b860
Strong Markov process stopping with payoff after independent phase-type random delay,
Coxian/diffusion cases. Directly blocks novelty from merely delaying stopping payoff.
Full PDF fetch returned NO_CONTENT_RETURNED, not unavailable; HTML inspected instead.
Not partial observation/unknown delay distribution guarantee for our application.

S6 Tree Search-Based Policy Optimization under Stochastic Execution Delay (ICLR2024),full:
https://proceedings.iclr.cc/paper_files/paper/2024/file/50e13537f46656a94a7acaf022921385-Paper-Conference.pdf
Stochastic delayed execution MDP and policy search; observed delay assumption matters.
Not a robust partially observed irreversible release guarantee. No RL implementation
or training admitted; cited to avoid treating action queues/delay as new.

S7 Precision Drug Dosing: Delay and Prolongedness of Action Effects (AAAI2023),abstract:
https://ojs.aaai.org/index.php/AAAI/article/view/26650
PAE-POMDP addresses prolonged action effects; not direct cargo-release timing dataset
or proof of a complete release solution. Physiological analogy does not equal data.

## Biological/source admission screen (no numerical data imported)

S8 primary RSC nanomotor study (2020), full HTML, article CC BY3.0 stated:
https://pubs.rsc.org/en/content/articlehtml/2020/nr/d0nr04415f
Supramolecular nanomotors with pH taxis. Conditioned HeLa medium pH6.0, endosomal
uptake/release context; release assay pH7.0 vs4.6. Article mentions extracellular
TME6.5-6.8 versus endosomal4.5-5.5 via cited literature. These are compartment-specific
conditions, not observed target-vs-feeder signal/noise distributions. pH taxis/motion
and cargo-release chemistry not a programmable binary instantaneous classification.
Article open license does not establish separately licensed raw sensor/latency data.

S9 primary nanofiber surgical buttress study, PMC full text:
https://pmc.ncbi.nlm.nih.gov/articles/PMC9930888/
Local scaffold, not navigating microrobot. Release sustained over days; cell-media
pH6.5 reported 70% doxorubicin released by day45, pH7.4 2% over same period. No
sensing-to-actuation latency law for a robot. Article figures/supplement are not an
admitted joint spatial sensor/release dataset. No extraction/fitting or reuse grant
inferred from readable article. Different drug/material/system, not conflicting
measurements to average into one delay.

S10 primary nanoparticles/microbubbles study (2016), full HTML, CC BY4.0 article:
https://preview-www.nature.com/articles/srep29321
pH-sensitive particles and focused-ultrasound microbubble delivery, in-vitro release
and in-vivo antitumor response. Passive/interstitial/endosomal and ultrasound effects
must not be converted to our arbitrary vascular trigger latency. Third-party material
license exceptions retained. No raw event/signal distribution admitted.

These readings support material-specific pH responsiveness and distinct compartments,
not the source-direction assertion that premature feeder-vessel release is the
DOMINANT failure. That premise remains UNVERIFIED in this bounded screen, not disproved.
No calibrated oxygen/enzyme/shear class, sensor noise/latency distribution, joint
vascular target/feeder field or real release-event dataset admitted. Human Protein
Atlas expression alone would not establish local causal trigger release; not inspected
here, so no HPA availability/rights conclusion. No >=3-signal-class G1 or80% G2 claim.

## Decision and limits

REJECT generic threshold/temporal filter/confidence-plus-latency composition as
invention. No exact uncovered claim identified; stop before code/synthetic scoring.
A specific delayed belief-state robust stopping formulation could be studied as an
established baseline if separately wanted, but its mathematical tractability or new
bound requires a new admission memo. Not authorized here. Original P08-09 science
G1-G4 remain OPEN; synthetic-first pivot does not establish biology or novelty.

Ten research sources across primary publications, publisher abstracts/institutional
record; community commentary not needed for technical admission. Bounded search,
not exhaustive literature/patent clearance. Source distinctions block simplistic
novelty claims but do not prove no new algorithm is possible. No external data/code
imported, no training/GPU, no held-out/frozen comparison or communication with authors.
